For children with atopic dermatitis (AD), early childhood stressful life events are associated with an increased risk for disease activity, according to a study published online Jan. 28 in the Journal ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...